Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.78 |
| ▸ | BCR | P11274 | 12/20 | 0.78 |
| ▸ | PRKCA | P17252 | 4/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 4/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | BTK | Q06187 | 1/20 | 0.66 |
| ▸ | ITK | Q08881 | 1/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22628286 | 0.90 | ABL1 (0.70) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL805400 | 0.89 | ABL1 (0.73) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL13437240 | 0.89 | ABL1 (0.73) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL30359587 | 0.88 | ABL1 (0.75) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL29555505 | 0.88 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL29005835 | 0.88 | ABL1 (0.75) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL2392 | 0.88 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL29366999 | 0.88 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL3210634 | 0.88 | ABL1 (0.75) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL18560357 | 0.88 | ABL1 (0.75) | ABL1BCRPRKCAPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319328-B2 | 4β-amino substituted podophyllotoxin derivative and preparation method therefor and use thereof | Tang, YaJie | 2022-05-03 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| EP-3782988-A1 | CRYSTAL FORM OF 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYLANILINE MONOHYDROCHLORIDE AND USE THEREOF | Arizest (Shanghai) Pharmatech Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-8912325-B2 | Process for preparation of imatinib and its mesylate salt | IND-SWIFT LABORATORIES LIMITED (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2011114337-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2011-09-22 | — | — | WO | disclosed |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| WO-2008135980-A1 | IMATINIB PRODUCTION PROCESS | CHEMAGIS LTD. (IL) | 2008-11-13 | — | — | WO | disclosed |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | SICOR INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080103305-A1 | Process for the preparation of imatinib | SICOR INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103305-A1 | Process for the preparation of imatinib | ABL1, ABL2, PDGFRA | ABL1 1/4885BCR 10/4885PRKCA 178/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ABL1 3074/4885BCR 3418/4885PRKCA 2201/4885 |
| US-11319328-B2 | 4β-amino substituted podophyllotoxin derivative and preparation method therefor and use thereof | WEE1, WEE2, CYP51A1 | ABL1 1033/4885BCR 1950/4885PRKCA 3030/4885 |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | PDGFRB, PDGFRA, KIT | ABL1 9/4885BCR 65/4885PRKCA 4/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | ABL1 3326/4885BCR 3333/4885PRKCA 2864/4885 |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | ABL1, ABL2, MET | ABL1 1/4885BCR 24/4885PRKCA 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.